We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The primary endpoint of Overall Survival (OS) in the Combined FOXFIRE Analysis showed no statistically significant difference between SIR-Spheres plus standard first-line chemotherapy...
Expert panel reaches uniform consensus that yttrium-90 microspheres is an appropriate option for patients with colorectal liver metastases Sirtex Medical Limited (ASX: SRX) today...
Company Reports Significant Increase in Both Referring Physicians and Hospitals Certified to Administer Procedure Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a...
Americas Region Generates More Than 79 Percent of Global Revenue Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), has announced that dose sales of SIR-Spheres® Y-90...
Increase of 18 Percent in Hospitals Certified to Administer Procedure Headline of release should read: Sirtex Medical Inc. Announces 21.2 Percent Dose Sales Growth of SIR-Spheres® Y-90...
Increase of 18 Percent in Hospitals Certified to Administer Procedure Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, liver...
http://www.fool.com.au/2015/03/16/is-sirtex-medical-limited-set-to-make-a-blockbuster-announcement/
Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), has announced that dose sales of SIR-Spheres® Y-90 resin microspheres in the Americas region grew more than 28...
First SIR-Spheres® microspheres treatment at Hospital Sirio-Libanes in Sao Paulo, Brazil Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of...
Forty Consecutive Quarters of Dose Sales Growth Globally Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, innovative liver cancer...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0.175 | 0.185 | 0.175 | 1547513 | 0.17956126 | DE |
26 | 0.05 | 40 | 0.125 | 0.195 | 0.125 | 1327475 | 0.16446012 | DE |
52 | 0.06 | 52.1739130435 | 0.115 | 0.195 | 0.056 | 1788827 | 0.1194771 | DE |
156 | -0.275 | -61.1111111111 | 0.45 | 0.65 | 0.056 | 2218211 | 0.21420635 | DE |
260 | -0.275 | -61.1111111111 | 0.45 | 0.65 | 0.056 | 2218211 | 0.21420635 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions